A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
Hoofdauteur: | Karim, Azrin |
---|---|
Andere auteurs: | Islam, Farzana |
Formaat: | Project report |
Taal: | English |
Gepubliceerd in: |
Brac University
2024
|
Onderwerpen: | |
Online toegang: | http://hdl.handle.net/10361/24372 |
Gelijkaardige items
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
door: Islam, Saidul
Gepubliceerd in: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
door: Ahmed, Nafisa
Gepubliceerd in: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
door: Meem, Manila
Gepubliceerd in: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
door: Hossain, Sadman Sanjid
Gepubliceerd in: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
door: Jahan, Nusrat
Gepubliceerd in: (2024)